



TQ therapeutics

GeneNovate Pitch Day

[27th June 2025]

(CAR-) T THERAPY IS ONE OF THE MOST NOVEL & PROMISING THERAPY APPROACHES

ATMPs – Cell & Gene Therapy

(CAR-) T cell therapies
have a **\$120bn**
market potential




Only **30,000**
patients
received CAR T



CURRENT MANUFACTURING METHOD OF CART THERAPIES ARE LENGTHY, LABOUR-INTENSIVE AND COSTLY

Problem

CURRENT CELL & GENE MANUFACTURING TAKES LONG, IS LABOREUS & EXPENSIVE



Note: CAPEX (e.g. Device costs, facilities...) are not included in the costs laid out

10.07.2025


TQ Therapeutics

TQx's WILL BRING THE THERAPY TO THE PATIENT WITH AN ULTRA SHORT EXTRACORPORAL APPROACH

TQx Solution


TQx EXTRACORPOREAL GENE THERAPY AT BEDSIDE:

Scalable & modular all-in-one automated extracorporeal targeted gene therapy platform for decentralized and stand-alone treatment from whole blood



SPECIFIC TARGET CELL SELECTION IS A MUST-HAVE FOR NEXT-GEN CELL MNF


TQx Cell Selection



- **Whole blood as starting material** as easier accessible more tolerable alternative to apheresis
 - binding of target cells from whole blood; flow through of non-target cells
 - competitive dissociation of target cells from matrix
 - release of bound target cells from matrix
- **Affinity based enrichment** of untouched cells
- Scalable and fast operation times (**<40 minutes**)
- Suitable for **commercial scale manufacturing** in an end sterilizable format
- Matrix compatible with standard methods of **genetic information transfer**
- Manufacture & sell jointly with **Fresenius**


TQx IS COMBING THE BEST OF THREE WORLDS BY OFFERING CGT IN AN ULTRA SHORT PROCESS AT THE PATIENTS BED-SIDE

TQx trinity



TQx WILL OFFER A PLATFORM BUSINESS MODEL, THAT ENABLES TQ therapeutics TO SCALE CGT ACROSS SEVERAL INDICATIONS

TQx Business Model



TQx REVENUE POTENTIAL


Bed-Side Device: 
(Partnered)

TQx Process on Cassette: € €

Therapies Platform: € € €

WE ARE LOOKING TO BRING OUR PLATFORM TO THE NEXT LEVEL AND INTO THE CLINC

Development timeline



TQ THERAPEUTICS TEAM



Dr. Christian Eckert
Co-Founder & CEO

- 20+ years experience in Biotech & Cell Therapy, Antibodies & Small Molecules, Exosomes
- 10 years experience in Clin. Op. & Clin. Dev
- Experience as Managing Director



Dr. Christian Stemberger
Co-Founder & CSO

- 15 years experience in Biotech & Cell Therapy
- Translational Immunology
- Inventor of 10+ field relevant patents on cell manufacturing & engineering



Sabine Radisch
Co-Founder & CTO

- 12 years experience in Biotech & Cell Therapy
- Technical Device/Product & Process Development
- Medical Device & consumables manufacturer mngt



Dr. Stefan Dreher
Co-Founder & COO

- 13 years experience in Biotech & Cell Therapy
- Process Development, Manufacturing & Supply Chain Lead in GMP environment
- CMO management



Christin Zündorf
Chief Business Officer

- 8+ years experience in strategy consulting in the pharmaceutical and life science industry
- Commercial strategy and organization design
- Venture Building



Our road to success:

From Biotech » Big Pharma

From Concept » Clinic

SHIFTING PARADIGMS IN CELL & GENE THERAPY

MAKING CHALLENGING DISEASES CURABLE - FOR EVERYONE

TQx IS AIMING FOR SERIES A FINANCING* IN Q1/2026 FOR

- TQx CLINICAL PHASE 1 TRIAL
- PROCESS PLATTFORM PARTNERSHIPS (Therapies Platform)

* Investment amount to be disclosed



Contact:

Christin Zündorf
Chief Business Officer
M: +49 1516 5083280
E: c.zuendorf@tqtherapeutics.com